Title : Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects.

Pub. Date : 2021 Apr

PMID : 33047859






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BI 655064 exhibited non-linear, saturable kinetics, with higher doses resulting in slower apparent clearance (0.514-0.713 mL min-1 ), and disproportionately higher total exposure (AUC0-inf ; 5610-7780 mug h mL-1 ) and maximum plasma concentration (15,700-21,300 ng mL-1 ) with 240 mg BI 655064. BI 655064 L1 cell adhesion molecule Mus musculus
2 BI 655064 exhibited non-linear, saturable kinetics, with higher doses resulting in slower apparent clearance (0.514-0.713 mL min-1 ), and disproportionately higher total exposure (AUC0-inf ; 5610-7780 mug h mL-1 ) and maximum plasma concentration (15,700-21,300 ng mL-1 ) with 240 mg BI 655064. BI 655064 L1 cell adhesion molecule Mus musculus